Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune Profiling.

Conrad VK, Dubay CJ, Malek M, Brinkman RR, Koguchi Y, Redmond WL.

Cytometry A. 2019 Feb;95(2):183-191. doi: 10.1002/cyto.a.23664. Epub 2018 Dec 20.

PMID:
30570217
2.

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.

Farhad M, Rolig AS, Redmond WL.

Oncoimmunology. 2018 Feb 20;7(6):e1434467. doi: 10.1080/2162402X.2018.1434467. eCollection 2018. Review.

3.

Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.

Emerson DA, Redmond WL.

BioDrugs. 2018 Jun;32(3):221-231. doi: 10.1007/s40259-018-0277-2. Review.

PMID:
29637478
4.

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.

Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.

5.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
6.

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.

Redmond WL, Linch SN.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2519-2522. doi: 10.1080/21645515.2016.1193277. Epub 2016 Jul 26.

7.

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM.

Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547.

8.
9.

Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.

McNamara MJ, Hilgart-Martiszus I, Barragan Echenique DM, Linch SN, Kasiewicz MJ, Redmond WL.

Cancer Immunol Res. 2016 Aug;4(8):650-7. doi: 10.1158/2326-6066.CIR-16-0022. Epub 2016 Jun 4.

10.

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E319-27. doi: 10.1073/pnas.1510518113. Epub 2016 Jan 4.

11.

Editorial: Advances in Combination Tumor Immunotherapy.

Curran MA, Fox BA, Redmond WL.

Front Oncol. 2015 Sep 22;5:198. doi: 10.3389/fonc.2015.00198. eCollection 2015. No abstract available.

12.

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

Linch SN, McNamara MJ, Redmond WL.

Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Review.

13.

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells.

McNamara MJ, Kasiewicz MJ, Linch SN, Dubay C, Redmond WL.

J Immunother Cancer. 2014 Sep 16;2:28. doi: 10.1186/s40425-014-0028-y. eCollection 2014.

14.

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.

Linch SN, Redmond WL.

Oncoimmunology. 2014 Mar 17;3:e28245. eCollection 2014.

15.

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Redmond WL, Linch SN, Kasiewicz MJ.

Cancer Immunol Res. 2014 Feb;2(2):142-53. doi: 10.1158/2326-6066.CIR-13-0031-T. Epub 2013 Nov 11.

16.

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor.

Crittenden MR, Savage T, Cottam B, Bahjat KS, Redmond WL, Bambina S, Kasiewicz M, Newell P, Jackson AM, Gough MJ.

PLoS One. 2013 Jul 25;8(7):e69527. doi: 10.1371/journal.pone.0069527. Print 2013.

17.

Professional development session for early career scientists at SITC 2012.

Capitini CM, Redmond WL, Shafer-Weaver KA.

J Immunother Cancer. 2013 Jun 27;1:6. doi: 10.1186/2051-1426-1-6. eCollection 2013.

18.

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Redmond WL, Triplett T, Floyd K, Weinberg AD.

PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4.

19.

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA.

Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Review.

20.

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD.

J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095.

21.

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Redmond WL, Gough MJ, Weinberg AD.

Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348.

22.

The role of OX40-mediated co-stimulation in T-cell activation and survival.

Redmond WL, Ruby CE, Weinberg AD.

Crit Rev Immunol. 2009;29(3):187-201. Review.

23.

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD.

Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484.

24.
25.

Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.

Redmond WL, Weinberg AD.

Crit Rev Immunol. 2007;27(5):415-36. Review.

PMID:
18197805
26.
27.

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.

Ruby CE, Redmond WL, Haley D, Weinberg AD.

Eur J Immunol. 2007 Jan;37(1):157-66.

28.

CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles.

Martinez X, Kreuwel HT, Redmond WL, Trenney R, Hunter K, Rosen H, Sarvetnick N, Wicker LS, Sherman LA.

J Immunol. 2005 Aug 1;175(3):1677-85.

29.

Peripheral tolerance of CD8 T lymphocytes.

Redmond WL, Sherman LA.

Immunity. 2005 Mar;22(3):275-84. Review.

30.

Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo.

Redmond WL, Marincek BC, Sherman LA.

J Immunol. 2005 Feb 15;174(4):2046-53.

31.

B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets.

Yadav D, Judkowski V, Flodstrom-Tullberg M, Sterling L, Redmond WL, Sherman L, Sarvetnick N.

J Immunol. 2004 Sep 15;173(6):3631-9.

32.
33.
34.

Cutting edge: T cell-mediated pathology in murine Lyme borreliosis.

McKisic MD, Redmond WL, Barthold SW.

J Immunol. 2000 Jun 15;164(12):6096-9.

Supplemental Content

Loading ...
Support Center